149 related articles for article (PubMed ID: 38381371)
1. [Bone marrow histology of cytopenias : Contribution to hematological differential diagnosis].
Kreipe H
Pathologie (Heidelb); 2024 Mar; 45(2):148-158. PubMed ID: 38381371
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow immunophenotyping by flow cytometry in refractory cytopenia of childhood.
Aalbers AM; van den Heuvel-Eibrink MM; Baumann I; Dworzak M; Hasle H; Locatelli F; De Moerloose B; Schmugge M; Mejstrikova E; Nováková M; Zecca M; Zwaan CM; Te Marvelde JG; Langerak AW; van Dongen JJ; Pieters R; Niemeyer CM; van der Velden VH
Haematologica; 2015 Mar; 100(3):315-23. PubMed ID: 25425683
[TBL] [Abstract][Full Text] [Related]
3. The level of bone marrow WT1 message is a useful marker to differentiate myelodysplastic syndromes with low blast percentage from cytopenia due to other reasons.
Baba M; Hata T; Tsushima H; Mori S; Sasaki D; Turuta K; Hasegawa H; Ando K; Sawayama Y; Imanishi D; Taguchi J; Yanagihara K; Tomonaga M; Kamihira S; Miyazaki Y
Intern Med; 2015; 54(5):445-51. PubMed ID: 25758068
[TBL] [Abstract][Full Text] [Related]
4. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
5. MDS overlap disorders and diagnostic boundaries.
Tanaka TN; Bejar R
Blood; 2019 Mar; 133(10):1086-1095. PubMed ID: 30670443
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of dysplastic changes in acquired aplastic anemia: A systematic study of bone marrow biopsies in children and adults.
Marchesi RF; Velloso EDRP; Garanito MP; Leal AM; Siqueira SAC; Azevedo Neto RS; Rocha V; Zerbini MCN
Ann Diagn Pathol; 2020 Apr; 45():151459. PubMed ID: 32000075
[TBL] [Abstract][Full Text] [Related]
7. Spectrum of Myelodysplastic Syndrome in Patients Evaluated for Cytopenia(s). A Report from a Reference Centre in Saudi Arabia.
AlMozain N; Mashi A; Alneami Q; Al-Omran A; Bakshi N; Owaidah T; Khalil S; Khogeer H; Hashmi S; Al-Sweedan S; Morris T; AlNounou R
Hematol Oncol Stem Cell Ther; 2022 Jun; 15(2):39-44. PubMed ID: 33227261
[TBL] [Abstract][Full Text] [Related]
8. [Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].
Schmitt-Graeff A; Mattern D; Köhler H; Hezel J; Lübbert M
Pathologe; 2000 Jan; 21(1):1-15. PubMed ID: 10663664
[TBL] [Abstract][Full Text] [Related]
9. [Clinically relevant possibilities and limits of differential diagnosis of megaloblastic anemia and myelodysplastic syndrome - refractory anemia type in bone marrow biopsies].
Vašeková P; Szépe P; Marcinek J; Balhárek T; Plank L
Vnitr Lek; 2016; 62(9):692-697. PubMed ID: 27715070
[TBL] [Abstract][Full Text] [Related]
10. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
11. Spectrum of hematological malignancies and peripheral cytopenias.
Jha A
J Nepal Health Res Counc; 2013 Sep; 11(25):273-8. PubMed ID: 24908530
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive analysis of cytopenias and bone marrow morphology in patients with a history of bariatric and metabolic surgery.
Bruehl FK; Bosler DS; Butsch WS; Farkas DH; Ondrejka SL
Int J Lab Hematol; 2022 Apr; 44(2):263-272. PubMed ID: 34668320
[TBL] [Abstract][Full Text] [Related]
13. Clinical presentation, diagnosis, and prognosis of myelodysplastic syndromes.
Foran JM; Shammo JM
Am J Med; 2012 Jul; 125(7 Suppl):S6-13. PubMed ID: 22735753
[TBL] [Abstract][Full Text] [Related]
14. Low blood counts: immune mediated, idiopathic, or myelodysplasia.
Valent P
Hematology Am Soc Hematol Educ Program; 2012; 2012():485-91. PubMed ID: 23233623
[TBL] [Abstract][Full Text] [Related]
15. Complete blood count and cell population data parameters from the Abbott Alinity hq analyzer are useful in differentiating myelodysplastic syndromes from other forms of cytopenia.
Hwang SM; Nam Y
Int J Lab Hematol; 2022 Jun; 44(3):468-476. PubMed ID: 34877795
[TBL] [Abstract][Full Text] [Related]
16. [Differential diagnosis of reactive cytopenias].
Menter T; Dirnhofer S; Tzankov A
Pathologie (Heidelb); 2022 Jul; 43(4):263-270. PubMed ID: 35925221
[TBL] [Abstract][Full Text] [Related]
17. Validation of a scoring system to establish the probability of myelodysplastic syndrome in patients with unexplained cytopenias or macrocytosis.
Rauw J; Wells RA; Chesney A; Reis M; Zhang L; Buckstein R
Leuk Res; 2011 Oct; 35(10):1335-8. PubMed ID: 21704372
[TBL] [Abstract][Full Text] [Related]
18. Unexplained chronic cytopenia: is it idiopathic cytopenia of undetermined significance or myelodysplastic syndrome.
Ramachandran P; Erdinc B; Sahni S; Avezbakiyev B
BMJ Case Rep; 2019 Oct; 12(10):. PubMed ID: 31630129
[TBL] [Abstract][Full Text] [Related]
19. Differences in the bone marrow histology between childhood myelodysplastic syndrome with multilineage dysplasia and refractory cytopenia of childhood without multilineage dysplasia.
Iwafuchi H; Ito M
Histopathology; 2019 Jan; 74(2):239-247. PubMed ID: 30062702
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic utility of the lymphoid screening tube supplemented with CD34 for Ogata score calculation in patients with peripheral cytopenia.
Muyldermans A; Florin L; Devos H; Cauwelier B; Emmerechts J
Hematology; 2019 Dec; 24(1):166-172. PubMed ID: 30334700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
